EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 3.0

Precision Oncology Clinical Trials: A Systematic Review of Phase II Clinical Trials with Biomarker-Driven, Adaptive Design

Hyerim Ha, Hee Yeon Lee, Jee Hyun Kim, Do Yeun Kim, Ho Jung An, SeungJin Bae, Hye-Sung Park, Jin Hyoung Kang

Cancer Research and Treatment · 15.10.2024 · 56 (4) · 991-1013

DOI: 10.4143/crt.2024.128 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cancer Research and Treatment, erschienen am 15.10.2024. Verfasst von Hyerim Ha und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Inha University Hospital, Inha University College of Medicine, Incheon, Korea. Hauptthemen laut MEDLINE: Precision Medicine, Biomarkers, Tumor, Clinical Trials, Phase II as Topic, Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Ministry of Food and Drug Safety.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Novel clinical trial designs are conducted in the precision medicine era. This study aimed to evaluate biomarker-driven, adaptive phase II trials in precision oncology, focusing on infrastructure, efficacy, and safety. We systematically reviewed and analyzed the target studies. EMBASE and PubMed searches from 2015 to 2023 generated 29 eligible trials. Data extraction included infrastructure, biomarker screening methodologies, efficacy, and safety profiles. Government agencies, cancer hospitals, and academic societies with accumulated experiences led investigator-initiated precision oncology clinical trials (IIPOCTs), which later guided sponsor-initiated precision oncology clinical trials (SIPOCTs). Most SIPOCTs were international studies with basket design. IIPOCTs primarily used the central laboratory for biomarker screening, but SIPOCTs used both central and local laboratories. Most of the studies adapted next-generation sequencing and/or immunohistochemistry for biomarker screening. Fifteen studies included an independent central review committee for outcome investigation. Efficacy assessments predominantly featured objective response rate as the primary endpoint, with varying results. Nine eligible studies contributed to the United States Food and Drug Administration’s marketing authorization. Safety monitoring was rigorous, but reporting formats lacked uniformity. Health-related quality of life and patient-reported outcomes were described in some protocols but rarely reported. Our results reveal that precision oncology trials with adaptive design rapidly and efficiently evaluate anticancer drugs’ efficacy and safety, particularly in specified biomarker-driven cohorts. The evolution from IIPOCT to SIPOCT has facilitated fast regulatory approval, providing valuable insights into the precision oncology landscape.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineBiomarkers, TumorClinical Trials, Phase II as TopicNeoplasmsHumansResearch DesignMedical Oncology

Stichwörter der Autor:innen

Adaptive designBiomarkersEfficacyIndependent central review committeesNeoplasmsPrecision medicineSafety

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Internal Medicine, Inha University Hospital, Inha University College of Medicine, Incheon, Korea.
  • Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  • Department of Internal Medicine, Dongguk University Ilsan Hospital, Goyang, Korea.
  • Division of Oncology, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.
  • College of Pharmacy, Ewha Womans University, Seoul, Korea.

Förderung

  • Ministry of Food and Drug Safety

Zitieren

APA

Ha, H., Lee, H. Y., Kim, J. H., Kim, D. Y., An, H. J., Bae, S., Park, H. S., & Kang, J. H. (2024). Precision Oncology Clinical Trials: A Systematic Review of Phase II Clinical Trials with Biomarker-Driven, Adaptive Design. Cancer Research and Treatment, 56(4), 991-1013. https://doi.org/10.4143/crt.2024.128

Vancouver

Ha H, Lee HY, Kim JH, Kim DY, An HJ, Bae S, et al. Precision Oncology Clinical Trials: A Systematic Review of Phase II Clinical Trials with Biomarker-Driven, Adaptive Design. Cancer Research and Treatment. 2024;56(4):991-1013. doi:10.4143/crt.2024.128

BibTeX
@article{Ha2024,
  author = {Ha, Hyerim and Lee, Hee Yeon and Kim, Jee Hyun and Kim, Do Yeun and An, Ho Jung and Bae, SeungJin and Park, Hye-Sung and Kang, Jin Hyoung},
  title = {Precision Oncology Clinical Trials: A Systematic Review of Phase II Clinical Trials with Biomarker-Driven, Adaptive Design},
  journal = {Cancer Research and Treatment},
  year = {2024},
  volume = {56},
  number = {4},
  pages = {991--1013},
  doi = {10.4143/crt.2024.128}
}
Kostenlos starten →